Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2015—The patented PrestoChill is an all-dry cryoembedding system from Milestone Medical that does not use liquid nitrogen, CO2, or isopentane. The 60-second freezing time prevents the formation of ice crystals. An automatic defrost cycle is provided to eliminate the potential formation of ice on the freezing platform.
July 2015—Rheonix showcased in June its Encompass Optimum research-use-only platform at the 115th General Meeting of the American Society for Microbiology. The Encompass Optimum is an automated system for building and implementing molecular assays as a nonclinical tool.
July 2015—The journal Lung Cancer published a paper demonstrating the economic implications to the U.S. health care system of using VeriStrat in guiding treatment of patients with advanced non-small cell lung cancer. The paper’s authors conclude that using Biodesix’s VeriStrat improves overall survival and decreases medical costs in the U.S. payer system.
July 2015—Eppendorf has added two screw-cap tubes in 15 mL and 50 mL sizes to its line of Eppendorf Tubes. The newly designed screw caps provide optimal sealing properties, and their grooved and multisurface side contour provide a secure, slip-free grip.
July 2015—Enzo’s TIMP-1 ELISA kit is designed to provide a useful tool for investigating the TIMP-1 levels in multiple human matrices and aims to advance the studies on TIMP-1 function. The assay format allows for quantitative detection of 30 pg/mL of TIMP-1 in various sample types including serum, plasma, saliva, urine, and tissue culture media.
July 2015—Euroimmun US announced the FDA 510(k) clearance of its EuroPattern System, which consists of a fluorescent microscope (oculars included for manual interpretation) and software that acquires, interprets, archives, and displays digital images of stained IFA slides.
July 2015—Biocartis presented liquid biopsy data from the company’s BRAF mutation study at the American Society of Clinical Oncology annual meeting in June. The study, in collaboration with Bart Neyns, MD, PhD, University Hospital Brussels, showed that BRAF oncogene mutations monitored in plasma from metastatic melanoma patients on Biocartis’ Idylla system were significantly associated with treatment response and progression.
June 2015—Horizon Discovery Group and ArcherDX have signed an original equipment manufacturer agreement in which Horizon’s reference materials will be supplied as a standalone product alongside ArcherDX’s Archer FusionPlex to aid customer validation of its ALK fusion assay kits. The ALK fusion tests can run on both Illumina and Ion Torrent next-generation sequencing platforms.
June 2015—Rosetta Genomics has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude Corp., a Fjord Ventures portfolio company. The acquisition is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.
June 2015—Beckman Coulter Diagnostics will distribute four new immunosuppressant drug user defined reagents as part of the company’s therapeutic drugs monitoring menu on its AU family of clinical chemistry systems.
